Baseline characteristics
| Controlled asthma | Uncontrolled asthma | ||
|---|---|---|---|
| Totally controlled (n=22) | Well controlled (n=47) | (n=42) | |
| Sex (men/women) | 10/12 | 21/26 | 22/20 |
| Age (years) | 48 (19–64) | 52 (22–71) | 48 (22–68) |
| Atopy (Phadiatop ratio) | 4.93 (0.13–96.5) | 5.56 (0.06–106) | 27.3 (0.15–128)*‡ |
| Pack years in all subjects | 0.9 (0–31) | 2.0 (0–64) | 0.2 (0–45) |
| Ex-smokers, n (%) | 13 (59) | 27 (57) | 25 (60) |
| Current smokers, n (%) | 7 (32) | 12 (26) | 10 (24) |
| Cigarettes/day in current smokers | 12.0 (3–20) | 14.7 (3–20) | 12.9 (3–15) |
| Ex-smokers, n (%) | 13 (59) | 27 (57) | 25 (60) |
| Pack years in all subjects | 0.9 (0–31) | 2.0 (0–64) | 0.2 (0–45) |
| Patients using ICS, n (%) | 5 (23) | 26 (55) | 30 (71)** |
| Dose (µg/day) in all subjects¶ | 0 (0–1000)§ | 200 (0–1200) | 450 (0–1000)*‡‡ |
| Dose (µg/day) in subjects using ICS¶ | 500 (400–2000) | 1000 (200–2000) | 800 (100–2000) |
| Patients using LABA, n (%) | 3 (14) | 15 (32) | 16 (38) |
| Pre-bronchodilator FEV1 (% predicted) | 101 (71–114)§ | 90 (34–129) | 87 (42–128)‡* |
| Pre-bronchodilator FEV1/FVC (%) | 80 (58–97)§ | 74 (39–88) | 73 (40–97)‡ |
| Reversibility FEV1 (%) | 8.7 (0.7–23.9) | 9.0 (1.5–23.3) | 10.7 (–2.2 to 38.4) |
| PC20 AMP (mg/ml) | 640 (8.1–640) | 100 (0.1–640) | 7.7 (0–640)***†‡‡ |
Values are medians (ranges), unless stated otherwise.
*p<0.05 or **p<0.01 or ***p<0.001 versus controlled, †p<0.001 versus well controlled, ‡p<0.05 or ‡‡p<0.001 versus totally controlled, §p<0.05 versus well controlled. Additional results are provided in Table E1 in the online supplement.
¶Dose equivalent of beclomethasone.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroids; LABA, long-acting β2 agonist, PC20 AMP, provocative concentration of AMP causing a 20% fall in FEV1; reversibility FEV1 (%), change in FEV1 expressed as increase in percentage predicted after 800 μg of albuterol.